{"filings":[{"id":860917,"accession_number":"0001193125-26-257390","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-06-04T20:06:58+00:00","items":["5.07"],"status":"ready","headline":"Amylyx stockholders elect directors, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected George Mclean Milne Jr., Ph.D. (76.9M for, 14.1M withheld) and Paul Fonteyne (86.3M for, 4.8M withheld) as Class II directors.","Ratified Deloitte & Touche as independent auditor for FY 2026: 102.0M for, 34.5K against, 5.6K abstain.","Approved non-binding advisory vote on named executive officer compensation: 77.5M for, 13.5M against, 21.1K abstain.","No other matters were voted on at the June 4, 2026 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94483,"accession_number":"0001193125-26-210286","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q1 net loss $41.3M; Phase 3 avexitide topline data in Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.3M ($0.37 per share) vs $35.9M ($0.42) in Q1 2025; cash used in operations.","Cash $279.8M at March 31, 2026, down from $317.0M; runway expected into 2028.","R&D expense rose to $27.6M, driven by avexitide trial costs and $4M Gubra milestone.","Phase 3 LUCIDITY for avexitide (PBH) enrollment complete; topline data in Q3 2026.","Early biomarker data from LUMINA Phase 1 for AMX0114 (ALS) expected at ENCALS June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106892,"accession_number":"0001193125-26-120691","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Amylyx updates corporate presentation: Phase 3 LUCIDITY enrollment complete, Phase 2 PREVENT analysis added","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed enrollment in Phase 3 LUCIDITY trial.","Added exploratory analysis of Phase 2 PREVENT study from ENDO 2025.","Completed enrollment for Cohort 2 of Phase 1 LUMINA trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106891,"accession_number":"0001193125-26-086629","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx reports FY2025 net loss of $144.7M; avexitide Phase 3 enrollment complete, topline data Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2025: $144.7M ($1.53/share) vs $301.7M ($4.43/share) in FY2024.","Phase 3 LUCIDITY trial of avexitide in PBH enrollment complete; topline data expected Q3 2026, potential launch 2027.","Cash, equivalents, and short-term investments $317.0M at Dec 31, 2025; cash runway into 2028.","R&D expenses decreased to $90.4M from $104.1M due to lower AMX0035 spending, offset by increased avexitide costs.","Selected AMX0318 (GLP-1 receptor antagonist) as development candidate for PBH; IND filing targeted 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106890,"accession_number":"0001193125-26-006991","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Amylyx selects GLP-1 antagonist AMX0318 as development candidate for post-bariatric hypoglycemia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AMX0318 is a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases.","Candidate identified through research collaboration with Gubra; Gubra eligible for >$50M in development and commercial milestones.","Handover of candidate triggers $4M milestone payment to Gubra; mid-single digit royalties on worldwide net sales.","Amylyx expects to initiate IND-enabling studies and file an IND for AMX0318, though no specific timeline was provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123213,"accession_number":"0001193125-25-268043","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q3 net loss narrows to $34.4M; cash $344M after $191M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.4M ($0.37/sh) vs $72.7M ($1.07/sh) in Q3 2024; R&D $19.9M, SG&A $16.2M.","Cash and securities $344M at Sept 30, up from $180.8M at June 30; cash runway into 2028.","Phase 3 LUCIDITY trial of avexitide recruitment completion expected Q1 2026; topline data Q3 2026.","Phase 1 LUMINA trial of AMX0114 in ALS fully enrolled cohort 1; early data at Dec symposium.","Plan to initiate Phase 3 trial of AMX0035 in Wolfram syndrome H2 2026 pending FDA alignment."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139886,"accession_number":"0001193125-25-200159","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amylyx launches $164M common stock offering at $10.00 per share to fund avexitide launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 17.5M shares (2.625M option) at $10.00/share; net proceeds ~$164M, up to ~$188.7M.","Proceeds to advance avexitide commercial readiness, R&D, working capital, and general corporate purposes.","Underwriting led by Leerink Partners and Guggenheim Securities; expected closing September 11, 2025.","Underwriters granted 30-day option to purchase up to 2.625M additional shares at offering price less discounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139885,"accession_number":"0001193125-25-189109","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Amylyx discontinues AMX0035 program for PSP after Phase 2b miss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AMX0035 failed to show differences vs placebo on primary or secondary outcomes at Week 24.","Company will discontinue Phase 2b trial and open-label extension; will not proceed to Phase 3.","Safety data consistent with prior AMX0035 studies.","ORION program for progressive supranuclear palsy (PSP) is discontinued entirely."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139884,"accession_number":"0000950170-25-104546","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q2 net loss narrows to $41.4M; cash $180.8M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.4M ($0.46 per share) vs $72.7M ($1.07) in Q2 2024; lower SG&A and R&D spend in ALS.","Cash, equivalents, and marketable securities $180.8M at June 30, 2025; runway expected through end of 2026.","Pivotal Phase 3 LUCIDITY trial of avexitide in PBH fully enrolled in 2025; topline data H1 2026; potential launch 2027.","Phase 2b ORION trial (AMX0035) in PSP unblinded analysis expected Q3 2025 to inform Phase 3 go/no-go.","FDA Fast Track granted for AMX0114 (antisense oligo) in ALS; early LUMINA Phase 1 data expected 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157480,"accession_number":"0001193125-25-135860","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amylyx shareholders elect three Class I directors; ratify Deloitte; approve say-on-pay proposal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Karen Firestone, Justin Klee, and Bernhardt Zeiher elected as Class I directors for term ending 2028. Firestone and Zeiher each had ~21.3M votes withheld; Klee had 1.5M.","Ratification of Deloitte & Touche as auditor for FY 2025 passed with 72.5M for vs 34.7K against.","Non-binding advisory vote on executive compensation passed with 33.1M for, 24.1M against, and 2.0M abstentions.","Total shares voted: ~72.5M on auditor proposal; broker non-votes of 15.4M on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157479,"accession_number":"0000950170-25-066355","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q1 net loss $35.9M, cash $204.1M; avexitide Phase 3 underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $35.9M ($0.42/share), down from $118.8M ($1.75/share) YoY on lower R&D and SG&A costs.","Cash, equivalents, and marketable securities $204.1M; cash runway expected through end of 2026.","Phase 3 LUCIDITY trial of avexitide in PBH dosed first patient; enrollment complete 2025, topline data H1 2026.","Phase 1 LUMINA trial of AMX0114 (ASO for ALS) dosed first patient; early cohort data expected in 2025.","Closed $65.5M public offering of 19.7M shares in Jan 2025; Phase 2b ORION (PSP) data expected Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175862,"accession_number":"0000950170-25-031303","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx reports Q4 net loss of $37.5M, cash runway extended through 2026 after $65.5M raise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2024 was $37.5M ($0.55 per share); FY2024 net loss of $301.7M ($4.43 per share).","Cash, equivalents & short-term investments were $176.5M at Dec 31, 2024; plus $65.5M raised in Jan 2025.","Phase 3 LUCIDITY trial of avexitide in PBH recruiting; topline data expected first half 2026.","Appointed Dan Monahan as Chief Commercial Officer to lead commercialization strategy.","R&D expenses fell to $22.9M in Q4 2024 from $44.9M in Q4 2023; SG&A fell to $17.1M from $52.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175861,"accession_number":"0001193125-25-004547","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amylyx prices 17.1M-share public offering at $3.50/sh for ~$56.9M net proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 17,142,857 common shares at $3.50 per share, with 30-day option for up to 2,571,428 additional shares.","Net proceeds expected to be ~$56.9 million ($65.5 million if over-allotment exercised in full).","Closing expected January 13, 2025; proceeds to fund commercialization prep, pipeline, working capital.","Underwriting agreement includes customary representations, warranties, and market standoff provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192764,"accession_number":"0001193125-24-286212","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Amylyx and Gubra collaborate on GLP-1 antagonist; milestones up to >$50M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration with Gubra to develop a novel long-acting GLP-1 receptor antagonist; Amylyx to make small upfront and research payments (not material).","Gubra eligible for >$50M in success-based development and commercialization milestones plus mid-single digit royalties.","Amylyx expects cash runway into 2026; upfront and research payments not material to the company.","Screening to identify lead development candidate for IND-enabling studies; Amylyx has option to lead development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192763,"accession_number":"0000950170-24-122779","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx reports Q3 net loss of $72.7M; cash $234.4M; pipeline updates on AMX0035, avexitide, AMX0114","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $72.7M ($1.07 loss per share) vs net income of $20.9M in Q3 2023; acquired IPR&D expense of $36.2M for avexitide.","Cash, cash equivalents and marketable securities of $234.4M as of Sept. 30, 2024, down from $309.8M at June 30, 2024; runway into 2026.","Positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome: met primary endpoint (C-peptide improvement), with stabilization across secondary measures.","Avexitide Phase 3 program in post-bariatric hypoglycemia on track to initiate in Q1 2025; topline data expected in 2026.","FDA placed clinical hold on AMX0114 ALS trial, requesting lower starting dose; Amylyx plans to start LUMINA trial in Canada by end of 2024/early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":88036000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192762,"accession_number":"0001193125-24-238572","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"HELIOS Phase 2: AMX0035 improves C-peptide AUC by +3.8 min*ng/mL at Week 24 in Wolfram syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: C-peptide AUC improved at Week 24 (ITT +3.8 min*ng/mL; Per Protocol +20.2) and sustained through Week 48 (+36.7).","Glycemic control: HbA1c decreased (-0.09% at Week 24 to -0.35% at Week 36); time in target glucose range increased (+5.2% to +12.3%).","All 12 participants showed stability/improvement on CGIC and PGIC; no serious AEs related to AMX0035; diarrhea most common.","FDA and EU granted Orphan Drug Designation; company plans to meet FDA to discuss Phase 3, update in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209202,"accession_number":"0000950170-24-093304","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q2 net loss $72.7M; revenue negative after RELYVRIO withdrawal; avexitide acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $72.7M ($1.07/share) vs net income $22.1M ($0.31) a year ago; revenue negative $(1.0)M after RELYVRIO/ALBRIOZA withdrawal.","Cash $309.8M at June 30, down from $373.3M at March 31; runway into 2026.","Acquired avexitide (GLP-1 antagonist) with FDA Breakthrough Therapy; PBH Phase 3 plan Q1 2025.","Restructuring $22.9M largely severance; headcount reduced after PHOENIX failure and product discontinuation.","R&D down to $23.3M, SG&A to $21.6M; cost cuts and pipeline shift from RELYVRIO."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":87620000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209201,"accession_number":"0001193125-24-177000","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Amylyx completes acquisition of Avexitide from Eiger for $35.1M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Avexitide from Eiger BioPharmaceuticals for $35.1 million plus cure costs and assumed liabilities.","Sale approved by U.S. Bankruptcy Court for Northern District of Texas on June 26, 2024; closed July 9, 2024.","Amylyx will handle development, manufacture, and commercialization of Avexitide post-closing.","Transaction follows Asset Purchase Agreement dated June 21, 2024, as previously disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227125,"accession_number":"0000950170-24-076339","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amylyx acquires Avexitide from bankrupt Eiger BioPharma for $35.1M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires substantially all assets for Avexitide, a GLP-1 receptor antagonist, from Eiger BioPharmaceuticals.","Total purchase price $35.1M plus determined cure costs capped at $277,703.63.","Transaction subject to Bankruptcy Court approval; Eiger filed Chapter 11 on April 1, 2024.","Deal includes assigned contracts and regulatory filings; closing expected after court order.","Amylyx deposits $1.755M into escrow as deposit per approved bid procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227124,"accession_number":"0001193125-24-156050","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amylyx shareholders elect Cohen, Quimi as directors; ratify Deloitte","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Joshua Cohen and Daphne Quimi elected as Class III directors with ~32.6M and ~32.5M votes for, respectively.","Deloitte & Touche LLP ratified as independent auditor for FY2024 with 52,023,591 votes for, 162,947 against.","Non-binding advisory vote on NEO compensation approved: 41,211,831 for, 2,708,178 against, 38,594 abstain.","Shareholders chose 'One Year' as preferred frequency for future say-on-pay votes (38,275,989 for one year).","Broker non-votes of 8,341,537 on director elections and executive compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227123,"accession_number":"0000950170-24-056254","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q1 net loss $118.8M; discontinues RELYVRIO/ALBRIOZA; inventory write-down $110.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $118.8M ($1.75 diluted per share) vs. net income of $1.6M in Q1 2023.","Net product revenue $88.6M, up 24% YoY; includes $110.5M non-cash inventory write-down due to product withdrawal.","Voluntarily discontinuing RELYVRIO/ALBRIOZA for ALS; existing patients transitioned to free drug program.","Cash $373.3M, expected runway into 2026; interim HELIOS Wolfram data show improvement; topline from 12 patients expected fall 2024.","Phase 3 ORION PSP trial data expected mid-2025; IND and clinical trial of AMX0114 in ALS planned for H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":88643000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227122,"accession_number":"0001193125-24-091463","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Interim Phase 2 data for AMX0035 shows clinically meaningful effects in Wolfram syndrome (n=8)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["C-peptide AUC increased +15.6 ng*min/mL at Week 24; 7 of 8 participants had shorter time to peak C-peptide.","HbA1c reduced by 0.26% on average; 6 of 8 improved; time in target glucose range improved by +7.1%.","Visual acuity improved in 5 of 8 participants; one participant changed from legally blind to sighted.","All 8 participants showed disease stability or improvement per CGIC and PGIC; no serious AEs related to AMX0035."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227121,"accession_number":"0001193125-24-086609","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["2.05","7.01","8.01","9.01"],"status":"ready","headline":"Amylyx pulls RELYVRIO from market after Phase 3 miss, cuts 70% of staff","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntarily discontinues RELYVRIO/ALBRIOZA in U.S. and Canada; no new patients after today.","Workforce reduced ~70%; expects $19M in severance charges; cash runway extended into 2026.","Current patients may transition to free drug program; PHOENIX Open Label Extension ongoing.","Interim data from Phase 2 HELIOS (AMX0035 in Wolfram) due April 2024; webcast Apr 10.","AMX0114 for ALS expects to start clinical trial in 2H 2024; ORION PSP interim analysis mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246019,"accession_number":"0001193125-24-067471","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Amylyx appoints Dr. Bernhardt Zeiher to board, fills Class I director vacancy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed March 14, 2024 as Class I director; term expires at 2025 annual meeting.","Also named to Nominating and Corporate Governance Committee, replacing Paul Fonteyne.","Zeiher was Chief Medical Officer at Astellas Pharma from 2018-2022; joined Entrada Therapeutics board in 2023.","Receives initial option grant (lesser of $570K value or 50K shares); 1/3 vests at one year, remainder over two years.","Annual retainer of $45,000 plus $5,000 for Nominating Committee service; eligible for annual option grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246018,"accession_number":"0001193125-24-062878","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Amylyx Phase 3 ALS trial misses primary endpoint; may withdraw RELYVRIO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PHOENIX trial: no significant difference on ALSFRS-R at Week 48 (p=0.667); secondary endpoints also missed.","Company may voluntarily withdraw RELYVRIO/ALBRIOZA from market; will decide within 8 weeks after regulatory discussions.","Promotion paused immediately; drug and patient support remain available for now.","Study enrolled 664 adults; safety profile consistent, no new signals.","Phase 3 ORION in PSP and Phase 2 HELIOS in Wolfram syndrome continue as planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246017,"accession_number":"0000950170-24-018409","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx reports FY 2023 net income $49.3M vs loss; product revenue $380.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 net product revenue $380.8M; Q4 revenue $108.4M vs $102.7M in Q3 2023.","Net income of $49.3M (diluted EPS $0.70) for 2023 vs net loss of $198.4M ($3.39 loss per share) in 2022.","Cash, cash equivalents and short-term investments of $371.4M at Dec 31, 2023 vs $355.0M at Sep 30, 2023.","Phase 3 PHOENIX trial topline data expected Q1/Q2 2024; Phase 3 ORION trial dosed first patient Dec 2023, data 2025-2026.","Appointed Camille Bedrosian CMO, Linda Arsenault CHRO, Dan Monahan GM & Head of U.S. Commercial in late 2023/early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":380786000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}